The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Assessing

MLA

Bello, Ricardo J., et al. The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud’s Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Assessing. June 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........0cabb9ad28b9f54f54a222b06f4c3201&authtype=sso&custid=ns315887.

APA

Bello, R. J., Cooney, C. M., Melamed, E., Follmar, K., Yenokyan, G., Leatherman, G., Shah, A. A., Wigley, F. M., Hummers, L. K., & Lifchez, S. D. (2017). The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud’s Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Assessing.

Chicago

Bello, Ricardo J., Carisa M. Cooney, Eitan Melamed, Keith Follmar, Gayane Yenokyan, Gwendolyn Leatherman, Ami A. Shah, Fredrick M. Wigley, Laura K. Hummers, and Scott D. Lifchez. 2017. “The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud’s Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Assessing,” June. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........0cabb9ad28b9f54f54a222b06f4c3201&authtype=sso&custid=ns315887.